Literature DB >> 9376270

Immunohistochemical expression of SKALP/elafin in squamous cell carcinoma of the oesophagus.

S Yamamoto1, H Egami, T Kurizaki, H Ohmachi, N Hayashi, T Okino, Y Shibata, J Schalkwijk, M Ogawa.   

Abstract

In this study, the immunohistochemical expression of a new inducible elastase inhibitor, SKALP (skin-derived anti-leucoproteinase)/elafin, in the tissue of squamous cell carcinoma and uninvolved oesophageal mucosa was studied using a polyclonal rabbit anti-serum against SKALP/elafin. The results were compared with the immunohistochemical staining of proliferating cell nuclear antigen (PCNA) and the TUNEL assay in serial sections. In non-malignant oesophageal mucosa, the expression of SKALP/elafin was localized in the cells of the stratified zone overlying the PCNA-positive basal zone. In oesophageal cancer, the incidence of the expression was significantly related to the degree of the differentiation of the tumour. Characteristically, the expression was almost limited in tumour cell nests that had a clear squamous phenotype. In tumour cell nests, the expression of SKALP/elafin was localized in the cells overlying PCNA-expressing cells and no expression was found in the cells that expressed PCNA; DNA fragmentation was often observed in the same cell layers as those in which SKALP/elafin immunoreactivity was found. This enzyme inhibitor is speculated to be involved in the induction of the cell differentiation and apoptosis of human squamous cell carcinoma cells of the oesophagus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9376270      PMCID: PMC2228093          DOI: 10.1038/bjc.1997.511

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

1.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas.

Authors:  P Basset; J P Bellocq; C Wolf; I Stoll; P Hutin; J M Limacher; O L Podhajcer; M P Chenard; M C Rio; P Chambon
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

Review 2.  Biochemical interactions of tumor cells with the basement membrane.

Authors:  L A Liotta; C N Rao; U M Wewer
Journal:  Annu Rev Biochem       Date:  1986       Impact factor: 23.643

3.  Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.

Authors:  M S Baker; P Bleakley; G C Woodrow; W F Doe
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

4.  Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials.

Authors:  M Nakajima; D R Welch; P N Belloni; G L Nicolson
Journal:  Cancer Res       Date:  1987-09-15       Impact factor: 12.701

5.  Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence.

Authors:  O Wiedow; J M Schröder; H Gregory; J A Young; E Christophers
Journal:  J Biol Chem       Date:  1990-09-05       Impact factor: 5.157

6.  Inhibition of tumor cell invasion through matrigel by a peptide derived from the domain II region in urinary trypsin inhibition.

Authors:  H Kobayashi; J Gotoh; N Kanayama; Y Hirashima; T Terao; D Sugino
Journal:  Cancer Res       Date:  1995-05-01       Impact factor: 12.701

7.  Metastatic potential correlates with enzymatic degradation of basement membrane collagen.

Authors:  L A Liotta; K Tryggvason; S Garbisa; I Hart; C M Foltz; S Shafie
Journal:  Nature       Date:  1980-03-06       Impact factor: 49.962

8.  Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells.

Authors:  J F Cajot; J Bamat; G E Bergonzelli; E K Kruithof; R L Medcalf; J Testuz; B Sordat
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

9.  Skin-derived antileucoproteases (SKALPs): characterization of two new elastase inhibitors from psoriatic epidermis.

Authors:  J Schalkwijk; A Chang; P Janssen; G J De Jongh; P D Mier
Journal:  Br J Dermatol       Date:  1990-05       Impact factor: 9.302

10.  Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells.

Authors:  R Reich; E W Thompson; Y Iwamoto; G R Martin; J R Deason; G C Fuller; R Miskin
Journal:  Cancer Res       Date:  1988-06-15       Impact factor: 12.701

View more
  7 in total

1.  Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.

Authors:  Huafeng Wei; Karl Erik Hellström; Ingegerd Hellström
Journal:  Gynecol Oncol       Date:  2012-03-16       Impact factor: 5.482

2.  The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer.

Authors:  Joseph A Caruso; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2010-09-07       Impact factor: 12.701

3.  Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival.

Authors:  Adam Clauss; Vivian Ng; Joyce Liu; Huiying Piao; Moises Russo; Natalie Vena; Qing Sheng; Michelle S Hirsch; Tomas Bonome; Ursula Matulonis; Azra H Ligon; Michael J Birrer; Ronny Drapkin
Journal:  Neoplasia       Date:  2010-02       Impact factor: 5.715

4.  High Expression and Clinical Significance of Elafin in Colorectal Cancer.

Authors:  Yun Liu; Yu Tian; Ting Wu; Yun Dai; Weihong Wang; Guigen Teng
Journal:  Gastroenterol Res Pract       Date:  2019-06-09       Impact factor: 2.260

5.  Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer.

Authors:  Kelly K Hunt; Hannah Wingate; Tomoya Yokota; Yanna Liu; Gordon B Mills; Fan Zhang; Bingliang Fang; Chun-Hui Su; Ming Zhang; Min Yi; Khandan Keyomarsi
Journal:  Breast Cancer Res       Date:  2013-01-15       Impact factor: 6.466

6.  The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase.

Authors:  J A Caruso; S Akli; L Pageon; K K Hunt; K Keyomarsi
Journal:  Oncogene       Date:  2014-09-08       Impact factor: 9.867

7.  Clinical significance of PI3 and HLA-DOB as potential prognostic predicators for ovarian cancer.

Authors:  Yanrong Li; Haixia Li; Baojun Yang; Jing Wei; Cheng Zhen; Limin Feng
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.